UroGen Pharma Ltd. short interest in 2021
In 2021, UroGen Pharma Ltd.'s disclosed short interest ran from 11.96% of shares outstanding on 15 Jan 2021 to 8.06% on 31 Dec 2021, a change of -3.90 percentage points. The year's high was 12.51% on 26 Feb 2021 and its low 7.31% on 15 Nov 2021, averaging 9.84% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 36.16 days on 29 Oct 2021. Full history: UroGen Pharma Ltd..
Cite this page
By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2021 in figures
- Start of year
- 11.96% (15 Jan 2021)
- End of year
- 8.06% (31 Dec 2021)
- Change
- -3.90 pp
- High
- 12.51% (26 Feb 2021)
- Low
- 7.31% (15 Nov 2021)
- Average
- 9.84%
- Highest days to cover
- 36.16 (29 Oct 2021)
- SEC filings marked
- 9
Every report in 2021
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2021 | 11.96% | 14.89 | |
| 29 Jan 2021 | 11.85% | 15.98 | |
| 12 Feb 2021 | 12.32% | 16.04 | |
| 26 Feb 2021 | 12.51% | 23.73 | |
| 15 Mar 2021 | 11.08% | 9.25 | |
| 31 Mar 2021 | 10.47% | 9.96 | 10-K filed, results (8-K) |
| 15 Apr 2021 | 10.64% | 17.57 | |
| 30 Apr 2021 | 10.50% | 24.65 | |
| 14 May 2021 | 10.47% | 20.04 | 10-Q filed, results (8-K) |
| 28 May 2021 | 11.01% | 24.35 | |
| 15 Jun 2021 | 10.20% | 19.76 | |
| 30 Jun 2021 | 9.55% | 14.11 | |
| 15 Jul 2021 | 9.40% | 9.82 | results (8-K) |
| 30 Jul 2021 | 9.21% | 15.70 | |
| 13 Aug 2021 | 9.94% | 16.25 | 10-Q filed, results (8-K) |
| 31 Aug 2021 | 9.89% | 21.15 | |
| 15 Sep 2021 | 9.19% | 25.78 | |
| 30 Sep 2021 | 8.29% | 28.58 | |
| 15 Oct 2021 | 7.85% | 34.89 | |
| 29 Oct 2021 | 7.82% | 36.16 | |
| 15 Nov 2021 | 7.31% | 13.58 | 10-Q filed, results (8-K) |
| 30 Nov 2021 | 8.13% | 8.29 | |
| 15 Dec 2021 | 8.44% | 13.73 | |
| 31 Dec 2021 | 8.06% | 11.89 |
See also: UroGen Pharma Ltd.'s full history · most shorted US stocks of 2021 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.